NCT04606784View on ClinicalTrials.gov

Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

June 15, 2021

Study Completion Date

June 15, 2021

Conditions
Covid19
Interventions
BIOLOGICAL

Ampion

Ampion, nebulized for inhalation

OTHER

Standard of Care

Standard of Care

Trial Locations (1)

80907

Research Site, Colorado Springs

Sponsors
All Listed Sponsors
lead

Ampio Pharmaceuticals. Inc.

INDUSTRY

NCT04606784 - Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress | Biotech Hunter | Biotech Hunter